UNMC
BREAKTHROUGHS FOR LIFE.®

Lung Cancer Study:
Chemotherapy Treatment Planning

Case 1: Squamous Cell NSCLC

In the following case, what chemotherapy treatment regimen would you likely choose as first line treatment for this person diagnosed with Stage IV squamous cell NSCLC:

Case 1:

56-year-old male; smoking history: 35 pack years, quit 5 years ago; presents with worsening shortness of breath

CT Scan – right lower lobe cavitary lesion with mediastinal lymphadenopathy and bilateral adrenal lesions

Biopsy of Adrenal – squamous cell carcinoma

MRI of Brain – negative

On Exam – performance status: ECOG-0, no other abnormalities identified

Lab – hemoglobin = 11 gm/dL

Kidney & Liver Function – normal

Patient is not interested in a clinical trial; but wants to be aggressive.

---

1. Given this scenario, what chemotherapy regimen are you most likely to choose as first line treatment? *(choose ONE best)*

    ___ A.   Carboplatin – Paclitaxel **(go to 2-A, page 2)**

    ___ B.   Carboplatin – Gemcitabine **(skip to 2-B, page 3)**

    ___ C.   Carboplatin – Vinorelbine **(skip to 2-C, page 4)**

    ___ D.   Cisplatin – Gemcitabine **(skip to 2-D, page 5)**

    ___ E.   Other, please specify _____ **(skip to Question 3, page 6)**

Throughout this survey, unless otherwise noted, all response choices are limited to one per question.

For both the case scenarios, the order of the questions asked is important. In these sections, respondent may not go back and change a prior answer.

Case 1:

56-year-old male; smoking history: 35 pack years, quit 5 years ago; presents with worsening shortness of breath

CT Scan – right lower lobe cavitary lesion with mediastinal lymphadenopathy and bilateral adrenal lesions

Biopsy of Adrenal – squamous cell carcinoma

MRI of Brain – negative

On Exam – performance status: ECOG-0, no other abnormalities identified

Lab – hemoglobin = 11 gm/dL

Kidney & Liver Function – normal

Patient is not interested in a clinical trial; but wants to be aggressive.

Case 1 <u>Scenario</u>, continues…

2-A) Your Case 1 patient ranked a group of 9 possible unwanted chemo drug "side effects" from "1" to "9" with "1" being the one they would MOST LIKE TO AVOID to "9" being the MOST TOLERABLE of the group.

Your patient's top choices of adverse effects they would MOST LIKE TO AVOID were:

1 = Hair Loss
2 = Nausea
3 = Vomiting

Now what would be your treatment choice? *(choose ONE best)*

___ A.   Carboplatin – Paclitaxel **(go to Q3, page 6)**

___ B.   Carboplatin – Gemcitabine **(go to Q3, page 6)**

___ C.   Carboplatin – Vinorelbine **(go to Q3, page 6)**

___ D.   Cisplatin – Gemcitabine **(go to Q3, page 6)**

___ E.   Other, please specify _____ **(go to Q3, page 6)**

Case 1:

56-year-old male; smoking history: 35 pack years, quit 5 years ago; presents with worsening shortness of breath

CT Scan – right lower lobe cavitary lesion with mediastinal lymphadenopathy and bilateral adrenal lesions

Biopsy of Adrenal – squamous cell carcinoma

MRI of Brain – negative

On Exam – performance status: ECOG-0, no other abnormalities identified

Lab – hemoglobin = 11 gm/dL

Kidney & Liver Function – normal

Patient is not interested in a clinical trial; but wants to be aggressive.

Case 1 Scenario, continues…

2-B) Your Case 1 patient ranked a group of 9 possible unwanted chemo drug "side effects" from "1" to "9" with "1" being the one they would MOST LIKE TO AVOID to "9" being the MOST TOLERABLE of the group.

Your patient's top choices of adverse effects they would MOST LIKE TO AVOID were:

1 = Hair Loss
2 = Nausea
3 = Vomiting

Now what would be your treatment choice? *(choose ONE best)*

____ A.   Carboplatin – Paclitaxel **(go to Q3, page 6)**

____ B.   Carboplatin – Gemcitabine **(go to Q3, page 6)**

____ C.   Carboplatin – Vinorelbine **(go to Q3, page 6)**

____ D.   Cisplatin – Gemcitabine **(go to Q3, page 6)**

____ E.   Other, please specify _____ **(go to Q3, page 6)**

Case 1:

56-year-old male; smoking history: 35 pack years, quit 5 years ago; presents with worsening shortness of breath

CT Scan – right lower lobe cavitary lesion with mediastinal lymphadenopathy and bilateral adrenal lesions

Biopsy of Adrenal – squamous cell carcinoma

MRI of Brain – negative

On Exam – performance status: ECOG-0, no other abnormalities identified

Lab – hemoglobin = 11 gm/dL

Kidney & Liver Function – normal

Patient is not interested in a clinical trial; but wants to be aggressive.

Case 1 Scenario, continues…

2-C) Your Case 1 patient ranked a group of 9 possible unwanted chemo drug "side effects" from "1" to "9" with "1" being the one they would MOST LIKE TO AVOID to "9" being the MOST TOLERABLE of the group.

Your patient's top choices of adverse effects they would MOST LIKE TO AVOID were:

1 = Hair Loss
2 = Nausea
3 = Vomiting

Now what would be your treatment choice? *(choose ONE best)*

___ A.   Carboplatin – Paclitaxel **(go to Q3, page 6)**

___ B.   Carboplatin – Gemcitabine **(go to Q3, page 6)**

___ C.   Carboplatin – Vinorelbine **(go to Q3, page 6)**

___ D.   Cisplatin – Gemcitabine **(go to Q3, page 6)**

___ E.   Other, please specify _____ **(go to Q3, page 6)**

Case 1:

56-year-old male; smoking history: 35 pack years, quit 5 years ago; presents with worsening shortness of breath

CT Scan – right lower lobe cavitary lesion with mediastinal lymphadenopathy and bilateral adrenal lesions

Biopsy of Adrenal – squamous cell carcinoma

MRI of Brain – negative

On Exam – performance status: ECOG-0, no other abnormalities identified

Lab – hemoglobin = 11 gm/dL

Kidney & Liver Function – normal

Patient is not interested in a clinical trial; but wants to be aggressive.

Case 1 Scenario, continues…

2-D) Your Case 1 patient ranked a group of 9 possible unwanted chemo drug "side effects" from "1" to "9" with "1" being the one they would MOST LIKE TO AVOID to "9" being the MOST TOLERABLE of the group.

Your patient's top choices of adverse effects they would MOST LIKE TO AVOID were:

1 = Hair Loss
2 = Dizziness
3 = Headache

Now what would be your treatment choice? *(choose ONE best)*

___ A.   Carboplatin – Paclitaxel **(go to Q3, page 6)**

___ B.   Carboplatin – Gemcitabine **(go to Q3, page 6)**

___ C.   Carboplatin – Vinorelbine **(go to Q3, page 6)**

___ D.   Cisplatin – Gemcitabine **(go to Q3, page 6)**

___ E.   Other, please specify _____ **(go to Q3, page 6)**